Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic® (semaglutide) was originally developed to treat type 2 diabetes in adults, with FDA approval limited to patients aged 18 and above. However, when physicians prescribe GLP-1 medications off-label for weight management, eligibility and age considerations shift based on clinical judgment, individual health status, and specific state regulations. Understanding these distinctions helps patients navigate treatment options effectively.

FDA Approval Age Requirements for Ozempic

The FDA approved Ozempic® specifically for adults aged 18 years and older with type 2 diabetes. This age threshold reflects safety and efficacy data gathered during clinical trials involving adult populations. The drug label does not authorize use in pediatric patients for diabetes management, though off-label pediatric use may occur under careful medical supervision in select cases of type 2 diabetes in adolescents.

When Ozempic® received its indication, the clinical trial participants included adults across multiple age groups, demonstrating consistent glucose-lowering effects. The 18-year minimum age requirement aligns with FDA standards for many chronic disease medications, ensuring participants have sufficient physical development and decision-making capacity. Patients younger than 18 would require specialized clinical assessment and potential referral to pediatric endocrinologists.

Weight Loss Use and Age Considerations Beyond FDA Label

Ozempic® is not FDA-approved for weight loss in any age group, though similar compounds like Wegovy® (semaglutide) carry explicit weight management approval for adults 18 and older. When physicians prescribe GLP-1 medications off-label for weight loss, they rely on emerging evidence and clinical judgment rather than formal FDA authorization. Age eligibility for this off-label use remains a conversation between patient and provider, with most guidance recommending the same 18+ threshold seen in diabetes populations.

Clinical research into GLP-1 therapy for adolescent weight management is ongoing, with some institutions exploring controlled use in patients with severe obesity and weight-related complications. However, standard clinical practice currently reserves semaglutide weight loss treatment for adults. Teens seeking GLP-1 therapy should consult pediatric obesity specialists who can evaluate individual medical circumstances, family history, and metabolic risk factors.

PlexusDx Eligibility and Personalized Semaglutide Therapy

PlexusDx serves adults across all 50 states seeking compounded semaglutide injections and other GLP-1 options, with no insurance requirement and no membership fees. Compounded Semaglutide Injection starts at $149/month across flexible commitment tiers, making personalized therapy accessible without flat per-compound pricing surprises. PlexusDx sources all medications from licensed 503A compounding pharmacies, ensuring pharmaceutical quality and sterility standards.

Patients working with PlexusDx complete a comprehensive health assessment to determine individual suitability for GLP-1 therapy. The company offers the Precision Peptide Genetic Test ($99 add-on after the first month of treatment) to identify genetic variants affecting peptide-pathway response, including GIPR rs1800437 and GLP1R rs6923761, enabling truly personalized dosing and medication selection. HSA and FSA accounts are eligible for PlexusDx medications, lowering out-of-pocket costs for qualified patients.

Special Populations: Seniors and Age-Related Considerations

Adults aged 65 and older can safely use GLP-1 medications including semaglutide, though dose adjustments and kidney function monitoring become increasingly important with advancing age. Older adults often take multiple medications, creating potential drug interactions that require careful review before starting GLP-1 therapy. Physicians typically begin with lower starting doses and titrate more slowly in senior populations to minimize gastrointestinal side effects.

Kidney function naturally declines with age, and GLP-1 medications are processed and eliminated through renal pathways, making baseline kidney assessment essential before treatment initiation in older adults. Many seniors also benefit from structured weight loss programs that combine medication with dietary coaching and physical activity adapted to mobility and joint health. PlexusDx supports older adults seeking GLP-1 therapy by offering telehealth consultations that assess individual health complexity and adjust treatment recommendations accordingly.

Medical Conditions That Affect Age-Based Treatment Decisions

Young adults with multiple weight-related comorbidities such as type 2 diabetes, hypertension, and sleep apnea may become candidates for GLP-1 therapy despite being closer to the 18-year threshold, because the metabolic benefits often outweigh risks when supervised appropriately. Conversely, older adults with certain gastrointestinal conditions, pancreatic history, or severe kidney impairment may not be suitable candidates regardless of age. Individual risk-benefit assessment always supersedes age-based assumptions in clinical practice.

Pregnancy status represents a critical consideration across all age groups; GLP-1 medications are generally not recommended during pregnancy due to limited safety data, and women of childbearing age should use reliable contraception while on semaglutide therapy. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should avoid GLP-1 medications entirely based on FDA black-box warnings. PlexusDx providers screen for these contraindications during the initial consultation to ensure safe treatment matching.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can teenagers take Ozempic or semaglutide for weight loss?

Standard clinical practice reserves semaglutide weight loss treatment for adults aged 18 and older. Adolescents with severe obesity and weight-related health complications may explore GLP-1 therapy through pediatric obesity specialists in research or specialized clinic settings, but this remains uncommon and requires careful medical evaluation. Parents should consult a pediatric endocrinologist or obesity medicine specialist to discuss individual options.

What clinical evidence supports GLP-1 use in older adults?

Multiple randomized controlled trials demonstrate that GLP-1 medications reduce body weight and improve cardiovascular outcomes in adults across age ranges, including seniors. The LEADER trial (liraglutide) and SUSTAIN trials (semaglutide) included participants over age 65, showing consistent glycemic control and modest weight reduction with acceptable safety profiles. Older adults often achieve meaningful metabolic benefits when kidney function is adequate and medications are carefully monitored.

Does PlexusDx have minimum age requirements for semaglutide therapy?

PlexusDx providers assess each patient individually to confirm medical suitability, with standard practice aligning to the 18-year-old threshold for GLP-1 therapy. The company serves adults across all 50 states via telehealth consultation, offering Compounded Semaglutide Injection starting at $149/month without insurance requirements. All treatment decisions are made collaboratively between the patient and a PlexusDx-affiliated healthcare provider.

Are GLP-1 medications safe for people over 75 years old?

GLP-1 medications can be safe in people over 75 when kidney function is preserved, blood pressure is stable, and gastrointestinal tolerance is monitored. Older adults often experience more pronounced nausea during the initial titration phase, requiring slower dose escalation and dietary adjustment. Baseline kidney and cardiac assessment is essential, as semaglutide use in advanced age demands closer clinical oversight than in younger populations.

How does PlexusDx Precision Peptide Genetic Testing help personalize treatment by age?

PlexusDx maps 14 pathways and 49 peptides through the Precision Peptide Genetic Test ($99 add-on), identifying variants like GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 that influence individual medication response. This test reveals genetic predispositions to obesity and metabolic dysfunction across all age groups, enabling providers to choose between semaglutide, tirzepatide, or dual-compound GLP-Squared therapy based on a patient's unique peptide-pathway profile rather than age alone.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves